Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03920800
Other study ID # CHUB-Salem Wehbe
Secondary ID
Status Completed
Phase
First received
Last updated
Start date March 1, 2019
Est. completion date November 20, 2019

Study information

Verified date July 2022
Source Brugmann University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Lesions classified as "High Grade Squamous Intra-epithelial Lesions" (HSIL) are pre-cervical lesions of the cervix, induced by infection with the Human Papilloma Virus (HPV). The detection and proper management of these lesions greatly reduces the incidence of invasive cervical cancer. Pap smear remains the most effective tool for early detection of low and high-grade cervical lesions. In Belgium, screening for cervical cancer is recommended every 3 years for women between 25 and 65 years old. HPV is a virus who possesses certain oncogenic genes who have the ability to inactivate tumor suppressor genes in the host cell. This promotes a tumorigenesis process within the tissues affected by the virus. The majority of human papillomavirus infections are transient and spontaneously cleared by host defense mechanisms, especially in the first two years after exposure. However, 10-20% of infections persist latently and may eventually lead to progression to invasive cervical cancer. Even high-grade lesions kan naturally be cleared, even more so if the patient is young and immuno-competent. Therefore, the management of HSIL lesions in young women has been modified and consists of adopting mainly a conservative attitude, with controls every 6 months for 2 years. This management makes it possible to avoid unnecessary conizations of the cervix which, in young nulliparous patients, are not devoid of heavy obstetric consequences during subsequent pregnancies (premature birth, perinatal mortality). Cervical conization will only be considered for lesions that progress during follow-up or that persist beyond 2 years. However, this type of follow-up requires that patients be compliant. Our study has two main objectives: - to determine the compliance of CHU Brugmann Hospital patients who have been proposed a conservative strategy for the management of HSIL lesions. - to identify the predictive factors for the persistence and / or progression of high-grade pre-cancerous dysplastic lesions.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date November 20, 2019
Est. primary completion date November 20, 2019
Accepts healthy volunteers
Gender All
Age group 18 Years to 35 Years
Eligibility Inclusion Criteria: - Patients followed within the CHU Brugmann Hospital (no private practices). - HSIL lesions confirmed by anatomopathologic analysis on cervical biopsies or cone specimen without evidence of invasive lesions Exclusion Criteria: - Invasive lesions

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Data extraction from medical files
Data extraction from medical files
Biological:
Immunohistochemistry
Immunohistochemistry with Ki67 and p16 antibodies on residual samples, if this had not been foreseen in the standard of care management of the patient.

Locations

Country Name City State
Belgium CHU Brugmann Brussels

Sponsors (1)

Lead Sponsor Collaborator
Catherine Vanpachterbeke

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary Patient observance Numeric value: 1 (optimal), 2 (acceptable), 3 (absent).
Groups having benefited from a conservative attitude: Optimal compliance: 4 consultations in 24 months and / or indication of conization. Acceptable compliance: 2 to 3 consultations in 24 months. Observance absent: 0 to 1 consultation in 24 months. Groups having benefited from conization:
Optimal compliance: 2 consultations after conisation. Acceptable compliance: 1 after consultation. Observance absent: 0 consultation after conisation.
Every six months over a period of 24 months
Primary Cytologic results of the cervico-uterine smear. Cytologic results of the cervico-uterine smear. Diagnose established by the anatomo-pathologist. Every six months over a period of 24 months
Primary Histologic results of the cervical biopsies Histologic results of the cervical biopsies.Diagnose established by the anatomo-pathologist. Every six months over a period of 24 months
Primary Extent of dysplastic lesions Defined as the number of quadrants reached by the lesion. Every six months over a period of 24 months
Primary Endocervix damage Is the endocervix affected by the HSIL lesion (yes or no) ? Every six months over a period of 24 months
Primary Immuno-histologic results Ki67 Percentage of Ki67 antibody reactivity on the cervix biopsies Every six months over a period of 24 months
Primary Immuno-histologic results p16 Percentage of p16 antibody reactivity on the cervix biopsies Every six months over a period of 24 months
Secondary Gestity Total number of pregnancies Every six months over a period of 24 months
Secondary Parity Total number of children born Every six months over a period of 24 months
Secondary Age at first patient visit Age at first patient visit 1 day
Secondary HIV status HIV positive or negative Every six months over a period of 24 months
Secondary Smoking status Smoking or non smoking Every six months over a period of 24 months
Secondary Response time to the convocation for colposcopy Time between the patient's appointment and the receipt of the convocation for colposcopy Up to 24 months
Secondary HPV status Positive or negative for HPV virus Every six months over a period of 24 months
Secondary Quality of colposcopic examinations Defined as satisfactory or unsatisfactory (junction area completely seen or not seen). Every six months over a period of 24 months
See also
  Status Clinical Trial Phase
Completed NCT04177641 - Evaluation of Thioldisulfide Balance in Cervical Preinvasive Lesions
Recruiting NCT05210348 - Clinical Evaluation of Detection of High Risk HPV in Urine
Not yet recruiting NCT04115787 - Conservative Management in Patients Diagnosed With Grade 2 or Grade 3 CIN
Completed NCT06325592 - Association Between Surgical Timing and Route of Total Hysterectomy After LEEP and Perioperative Risk in Patients With Cervical HSIL
Active, not recruiting NCT02576561 - Safety and Efficacy Study of TVGV-1 Vaccine to Treat HPV Induced Cervical HSIL Phase 2
Active, not recruiting NCT05613283 - Primary Cervical Cancer Screening by Self-sampling HPV Test
Not yet recruiting NCT06333743 - Laser Ablation in the Treatment of High-grade Cervical Lesions N/A
Completed NCT03239223 - Study of Topical ABI-1968 in Subjects With Precancerous Cervical Lesions From Human Papillomavirus (HPV) Infection Phase 1
Not yet recruiting NCT06233331 - Use of ACU-D1 in HPV Associated Vulvar and Perianal Lesions in People With HIV Phase 1